Our mission is to develop innovative tools and approaches for the prevention of opportunistic infections affecting production animals (sheep, cattle, poultry, pigs) and domestic animals (dogs, horses) for which there are medical needs that have yet to be met.
Our ambition is to make widely available vaccines and neonatal immunostimulants that combine:
- Harmlessness with, in particular, no risks of renewed virulence,
- A clear and comprehensive regulatory profile,
- A pharmaceutical format while facilitating production, transport and use,
- A simple treatment protocol, requiring a single application (no need for booster shots), thereby promoting proper usage.
The availability of such drugs is all the more important as many animal infections are zoonoses that are transmissible to humans.
Currently, the pathologies targeted by the products we are developing are parasitic diseases:
- Ovine toxoplasmosis (infectious agent Toxoplasma gondii ),
- Bovine neosporosis (infectious agent Neospora caninum ),
- Canine leishmaniasis (infectious agent Leishmania infantum ),
- Equine protozoal myeloencephalitis (infectious agent Sarcocystis neurona ou Neospora haghesi),
- Cryptosporidiosis in young ruminants (infectious agent Cryptosporidium parvum ).
In essence, the drivers of these diseases are parasites from the Apicomplexan family. They are unicellular organisms (eukaryotes) which, given the devastation they can cause among farm animals, not only have serious consequences in animals, but also on human health. They therefore have a significant socio-economic impact that needs to be examined with great attention.
Their importance in terms of veterinary and human health is therefore considerable.
- Aenean eget mi eget
- Sed arcu eros lacinia
- Duis dictum purus
- Integer sodales justo
- Etiam in sem et lectus